top of page
The Professional Network for Healthcare Experts
ImmunityBio begins European patient treatment with Anktiva plus BCG for bladder cancer
ImmunityBio has begun treating patients in Europe with Anktiva plus BCG for a defined form of BCG-unresponsive bladder cancer, marking an early commercial-access milestone following its existing European authorisation.
nuaxia
14 hours ago2 min read
FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer
The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population.
nuaxia
Oct 152 min read
bottom of page